Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

BACKGROUND: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody-dependent cell-mediated c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fayette, Jérôme, Wirth, Lori, Oprean, Cristina, Udrea, Anghel, Jimeno, Antonio, Rischin, Danny, Nutting, Christopher, Harari, Paul M., Csoszi, Tibor, Cernea, Dana, O’Brien, Paul, Hanley, William D., Kapp, Amy V., Anderson, Maria, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Vermorken, Jan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086582/
https://www.ncbi.nlm.nih.gov/pubmed/27843803
http://dx.doi.org/10.3389/fonc.2016.00232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086582/
https://www.ncbi.nlm.nih.gov/pubmed/27843803
http://dx.doi.org/10.3389/fonc.2016.00232

Ejemplares similares